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1  |  INTRODUCTION
Mutations in isocitrate dehydrogenase (IDH) 1 and 2 occur in 
the majority of diffuse infiltrating gliomas. The IDH1 R132H 
mutation (IDH1 mut) is present in approximately 80% of grade 
II-III gliomas and secondary glioblastoma that progressed from 
low-grade astrocytoma.1 Mutations in IDH2 are much less 
common and are mutually exclusive with mutations in IDH1. 
IDH1 and IDH2 mutations are specific to codons that encode 
for arginine, an important amino acid in the catalytic domain 
of these enzymes. Most IDH1 mutations have been identified 
at the Arg132 codon (R132), and mutations in IDH2 have 
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Abstract
The discovery of the IDH1 R132H (IDH1 mut) mutation in low-grade glioma and 
the associated change in function of the IDH1 enzyme has increased the interest in 
glioma metabolism. In an earlier study, we found that changes in expression of genes 
involved in the aerobic glycolysis and the TCA cycle are associated with IDH1 mut. 
Here, we apply proteomics to FFPE samples of diffuse gliomas with or without IDH1 
mutations, to map changes in protein levels associated with this mutation. We ob-
served significant changes in the enzyme abundance associated with aerobic glycoly-
sis, glutamate metabolism, and the TCA cycle in IDH1 mut gliomas. Specifically, the 
enzymes involved in the metabolism of glutamate, lactate, and enzymes involved in 
the conversion of α-ketoglutarate were increased in IDH1 mut gliomas. In addition, 
the bicarbonate transporter (SLC4A4) was increased in IDH1 mut gliomas, support-
ing the idea that a mechanism preventing intracellular acidification is active. We also 
found that enzymes that convert proline, valine, leucine, and isoleucine into gluta-
mate were increased in IDH1 mut glioma. We conclude that in IDH1 mut glioma me-
tabolism is rewired (increased input of lactate and glutamate) to preserve TCA-cycle 
activity in IDH1 mut gliomas.
K E Y W O R D S
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been identified at the Arg140 codon (R140) and Arg172 codon 
(R172).2 Glioma patients with IDH1/2 mutations have a signifi-
cantly better prognosis compared with patients without these 
mutations.2 IDH1 and IDH2 mutations occur early in gliom-
agenesis and change the metabolic function of these enzymes. 
IDH1 mut leads to the production of excessive amounts of the 
oncometabolite 2-hydroxyglutarate (2-HG) in glioma cells.3 
The identification of the mutations in IDH1 and IDH2 and their 
relative positive effects on the prognosis compared with IDH1 
wild-type (IDH1 wt) glioma patients has increased interest in 
glioma metabolism in the brain.
Multiple preclinical models have provided possibilities to study 
the oncogenic properties of IDH1/2 mutations compared with 
IDH1 wt. In these models epigenetic regulation, cancer cell dif-
ferentiation, and metabolism are shown to be altered.3 The IDH1 
mut induces changes in the concentration of tricarboxylic acid 
(TCA) cycle intermediates and lipid metabolites.4,5 In vitro and 
in vivo studies demonstrated that the inhibition of IDH1/2-mutant 
enzymes decreases intracellular D-2-hydroxyglutarate (D-2HG) 
levels and reverses epigenetic dysregulation.6,7 Gene expression 
profiles of large cohorts of glioma and acute myeloid leukemia 
have shown that IDH1/2 mutant tumors display a distinct gene ex-
pression profile enriched for genes expressed in progenitor cells.8 
Metabolic flux analyses have shown that IDH1 mut render tumor 
cells more dependent on citrate and fatty acids under hypoxia as 
compared with IDH1 wt cells and this metabolic reprogramming 
results in decreased cell growth of IDH1 mut cells upon hypoxia.9
By quantitative PCR the RNA expression of the enzymes 
part of the aerobic glycolysis and the TCA cycle were previ-
ously studied. The RNA expressional changes were found in 
the enzymes of the TCA cycle (increased) and aerobic glycoly-
sis (LDHA decreased and LDHB increased).10 More recently, 
a relationship between the IDH1 mut and lactate and gluta-
mate dependency in glioma has been proposed.11,12 Based 
on targeted RNA sequencing of a large series of metabolic 
enzymes, it was shown that enzymes transporting glutamate 
and lactate into the cell and enzymes converting lactate and 
glutamate into α-ketoglutarate are upregulated in IDH1 mut 
gliomas.11 It was suggested that IDH1 mut gliomas depend 
on lactate and glutamate as metabolic substrates to alleviate 
metabolic stress as a result of defective isocitrate processing.11
In this study we validate previously obtained RNA 
expression data at the protein level and in addition studied the 
pentose phosphate pathway, TCA cycle, aerobic glycolysis, 
glutaminolysis, fatty acid metabolism, GABA shunt, and amino 
acid catabolism. To perform the proteomics mapping of the 
pathways, FFPE tissue samples of astrocytomas, oligodendro-
gliomas and GBMs were investigated. The samples were ana-
lyzed using both data-dependent analysis (DDA) and targeted 
mass spectrometry. First, data-dependent LC-MS analyses were 
performed to obtain a general overview of the abundance of 
proteins in the samples and to identify the most prominent dif-
ferences in metabolic enzymes between IDH1 mut and wild-
type tumors. Subsequently, the DDA data were used to develop 
a targeted semiquantitative multiplex method for 64 proteins re-
lated to the various metabolic pathways to obtain insight in the 
metabolic consequences of the IDH1 mutation. We observed 
that in IDH1 mut gliomas the enzymes of the aerobic glycolysis, 
glutaminolysis, and amino acid catabolism were most affected.
2 |  MATERIALS AND METHODS
Unless otherwise noted, all chemicals were purchased from 
Sigma-Aldrich (Saint Louis, MO) and all solvents were pur-
chased from Biosolve (Valkenswaard, The Netherlands).
2.1 | Samples
FFPE tissue samples of surgically resected gliomas from 48 
patients were used. All these gliomas are classified based on 
the most recent guidelines provided by WHO.13 The set in-
cluded 18 astrocytomas (IDH1 R132H and TP53 mutated), 
11 oligodendroglioma (IDH1 R132H and 1p/19q loss), and 
19 GBM (IDH1 wt). Additional patient characteristics can be 
found in Table 1. The use of patient material was approved 
by the Institutional Review Board of the Erasmus MC, 
Rotterdam, the Netherlands (nr MEC 221.520/2002/262; 
date of approval 22 July 2003, and MEC-2005-057, date of 
approval 14 February 2005). Patients gave written informed 
consent to use their tissue for research purposes.
2.2 | Sample preparation
H&E stained sections of 4 µm were microscopically assessed 
for at least 70% tumor cells. For proteomic analyses adjacent 
T A B L E  1  Patient data
Groups Grade
Average age 
(min-max) IDH1 R132H 1p 19q co-deletion TP53 mutation
Astrocytoma (n = 18) II(12), III(6) 43.6 (27-68) 18 0 18
GBM primary (n = 19) IV(19) 51.9 (29-69) 0 0 7
Oligodendroglioma 
(n = 11)
II(11) 49.3 (34-61) 11 11 1
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8 µm sections were collected in LoBind Eppendorf tube. The 
tissue section was de-paraffinized by xylene (98%), hydrated 
with different concentrations of ethanol, sequentially 100%, 
70%, 50%, and 0%, and all steps were followed by centrifugation 
with an Eppendorf centrifuge at maximum speed for 5 minutes. 
After each step the supernatant was discarded before proceeding 
to the next step. After the final step the samples were stored at 
−80°C until the time of digestion. To all samples 100 µL lysis 
buffer was added containing 1% SDC (sodium deoxycholate) 
in 0.3 M Tris (pH 8). The samples were disrupted by sonifi-
cation for 2 min at 70% amplitude at a maximum temperature 
of 25°C (Branson, Ultrasonic, Danbury, CT). Subsequently, the 
samples were incubated for 90 minutes at 90°C. Five microliter 
of 0.1 M DTT (dithiothreitol) was added to the samples and in-
cubated for 30 minutes at 60°C. Subsequently, 5 µL of 375 mM 
IAA (iodoacetamide) was added and incubated at room tem-
perature for 30 minutes in a dark environment. Next, 300 ng 
of trypsin (Promega, Madison, WI) was added to each sample 
and after overnight incubation at 37°C, 2.5 µL 25% TFA was 
added to each sample and centrifuged at 20,000 g for 30 min-
utes. Supernatants of all samples were transferred to a 96 well 
plate and desalted. For the automated sample processing the 
Assay MAP Bravo platform (Agilent technologies, Santa Clara, 
CA) was used. C18 cartridges were primed with 100 µL 50% 
ACN/ 0.1% TFA and equilibrated with loading buffer (0.1% 
TFA/water). Hundred microliter of sample was loaded onto the 
C18 cartridge. After washing the cartridges with 100 µL load-
ing buffer, the desalted peptides were eluted in 25 µL elution 
buffer: 70% ACN/0.1% TFA. Subsequently, the samples were 
dried using a vacuum centrifuge (Savant SC210A, Thermo 
Fisher Scientific). Samples were dissolved in 120 µL aqueous 
0.1% TFA and the total volume of each sample was divided over 
five 96 well plates. Next, plates were sealed and stored at 4°C 
until the LC-MS measurements were performed.
2.3 | Nano-LC data-dependent mass 
spectrometry measurements
Samples were analyzed by nano-LC (Ultimate 3000RS, Thermo 
Fisher Scientific, Germering, Germany) coupled to a Q Exactive 
HF mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). The samples were analyzed with the same method and 
settings as described previously.14 The LC-MS/MS proteomics 
data was deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository with the dataset identifier PXD016697.
2.4 | PRM measurements
PRM analyses were performed on the same nano-LC Orbitrap 
Q Exactive HF system as the DDA measurements. A shorter 
30  minutes gradient is used on the nano-LC system under 
similar LC conditions as for the DDA measurements. A quad-
rupole isolation window of 0.6  m/z units, an AGC target of 
1 × 106 ions, a maximum fill time of 120 ms, and an Orbitrap 
resolving power of 60,000 at 200 m/z were used. A normalized 
collision energy (NCE) of 27% was used for all peptides to-
gether with a retention time window of 4 minutes for each pep-
tide. Eventually, the results for all proteins were evaluated and 
for each protein the two best performing peptides were selected. 
Targeted MS/MS methods could be successfully developed for 
117 peptides belonging to 64 proteins (see Table S1). It was 
not possible to analyze all targets in a single method with the 
required sensitivity and retention time window. For this reason 
different methods were created, all containing a subset of the 
targeted peptides. The LC-MS/MS PRM proteomics data was 
deposited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD016698.
2.5 | Data processing and analysis DDA
MaxQuant 1.6.1.0 (http://www.coxdo cs.org/doku.
php?xml:id=maxqu ant:start ) was used to analyze the DDA 
data; default settings were used unless indicated otherwise. 
All raw files were loaded and the human subset of the uniprot_
sprot_2015-10 database was selected; Homo sapiens species re-
striction; 20,194 sequences, a maximum of two miss cleavages, 
oxidation as a variable modification of methionine, carbamido-
methylation as a fixed modification of cysteine, and trypsin was 
set as enzyme. The label free quantitation option with matching 
between runs was used. The quantitative values for all identi-
fied protein groups were further analyzed in Perseus 1.6.1.2 
(http://www.coxdo cs.org/doku.php?xml:id=perse us:start ). The 
data were annotated, log2 transformed, and imputation (replace 
value from normal distribution) was applied for missing values. 
Subsequently, hierarchical clustering and statistical analyses 
were performed to generate both heat maps and volcano plots.
2.6 | Data processing and analysis 
PRM data
The PRM data were analyzed using Skyline version 
3.5.0.9320 MacCoss Lab Software, Seattle, WA (https ://skyli 
ne.gs.washi ngton.edu/labke y/proje ct/home/softw are/Skyli 
ne/begin.view); fragment ions for each targeted mass were 
extracted and peak areas were integrated. Each fragment ion 
was visually inspected for interference and only fragment 
ions without interference in the integrated area were used and 
summed for further analyses. For all peptides, the areas were 
exported to Excel and correlation plots of peptides from the 
same protein were created. The values for all targeted pro-
teins were imported in Perseus where the same analyses were 
performed as mentioned above for the DDA data.
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3 |  RESULTS
The LC-MS analyses of 18 astrocytomas (IDH1 R132H 
and TP53 mutated), 11 oligodendroglioma (IDH1 mut and 
1p/19q loss), and 17 GBM (IDH1 wt) resulted in the iden-
tification of 1,509 protein groups. A hierarchical clustering 
of this dataset yielded two main clusters largely overlap-
ping with the IDH1 status (Figure 1). The first cluster con-
sisted of all but one GBM sample (all IDH1 wt), and two 
IDH1 mut samples (one oligodendroglioma and one astro-
cytoma). The other main cluster consisted of the rest of 
the samples with the IDH1 mut (gliomas graded 2 and 3), 
while one GBM IDH1 wt was present. The tumor samples 
harboring the co-deletion of 1p/19q (defining oligodendro-
glioma) were not discerned.
Twenty-eight proteins with functions in glycolysis, pen-
tose phosphate pathway, TCA cycle, aerobic glycolysis, 
glutaminolysis, fatty acid metabolism, GABA shunt, and 
catabolism of amino acids appeared to be differentially ex-
pressed between the IDH1 mut and IDH1 wt group (Figure 2). 
To more precisely map qualitative and quantitative differ-
ences in abundance between the two groups, a targeted PRM 
mass spectrometry method was developed for 70 selected 
proteins related to these pathways. The relative quantity of 
64 of these 70 proteins could be determined by PRM. For 
53 proteins the relative quantity was based on two peptides; 
for the other 11 proteins quantitation was based on a single 
peptide. The normalization of the data was performed on UV 
intensity and could be validated based on actin abundance. 
The actin abundance between the IDH1 wt group and the 
IDH1 mut group was not statistically significant. In the IDH1 
wt group two outliers with a significant lower abundance of 
actin (ACTC1) were observed and these samples were ex-
cluded from the analyses.
Of the 64 proteins analyzed by PRM, the abundance of 
48 was significantly different between the IDH1 mut and 
IDH1 wt sample group when applying an FDR correction 
of 0.05 (Figure 3 and Table 2). The ratio of the quantified 
enzymes between IDH1 mut and IDH1 wt sample group 
is shown in a scheme of the glycolysis, pentose phosphate 
pathway, TCA cycle, and the glutaminolysis metabolic 
pathways (Figure 4). The largest shifts in the abundance of 
enzymes between tumors with and without IDH1 mutation 
are observed in the glutaminolysis and aerobic glycolysis 
(Figure 5). The ratios between LDHA and LDHB (enzymes 
that are involved in pyruvate conversion into lactate and 
lactate into pyruvate, respectively) and the transporters 
that import and export lactate (SLC16A3 and SLC16A7, 
respectively) are shown in Figure 5A. The ratios of these 
enzymes indicate that LDHB and SLC16A7 are higher in 
abundance in contrast to LDHA and SLC16A3 in the IDH1 
mut group. This indicates that lactate import and its con-
version in pyruvate is increased in IDH1 mut gliomas if 
one assumes that the abundance of these enzymes is associ-
ated with the concentration of their substrates and products. 
Figure 6 shows the abundances of enzymes relating to the 
GABA shunt, fatty acid metabolism, valine, leucine, and 
isoleucine degradation (ABAT (GABA shunt)); ECHS1 and 
MLYCD (fatty acid metabolism); and BCKHA, BCKHB, 
and HIBCH (valine, leucine, and isoleucine degradation). 
The levels of these enzymes, except MLYCD, were signifi-
cantly elevated in IDH1 mut gliomas. For MLYCD, a regu-
lator of fatty acid metabolism, no difference was observed 
between the two groups.
F I G U R E  1  Heat map of DDA proteomics results of GBM, Astrocytoma, and Oligodendroglioma samples. Hierarchical clustering displayed 
as dendrograms. The protein abundances in each sample are represented as intensities log2 transformed and missing values were imputated 
by using background levels (a scale from red to green (high to low), pink = IDH1 wt, and blue = IDH1 mut)
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4 |  DISCUSSION
Previously, we showed that RNA expression levels of aerobic 
glycolysis and the TCA-cycle enzymes change in IDH1 mut 
compared with IDH1 wt glioma.10 In this study we confirmed 
these changes on the protein level. In addition, we included 
a number of connecting pathways to obtain a more complete 
view of the metabolic effects of these changes. To this end 
proteins of glycolysis, pentose phosphate pathway, aerobic 
glycolysis, fatty acid metabolism, GABA shunt, and catabo-
lism of amino acids were included in our analyses. The most 
dominant changes between IDH1 mut and IDH1 wt gliomas 
were observed in enzymes and transporter proteins related 
to aerobic glycolysis and glutaminolyses. These observa-
tions confirm the previous findings at the RNA level10-12 and 
strengthen the theory that both glutamate and lactate are im-
ported and converted into α-ketoglutarate in IDH1 mut glio-
mas, to decrease metabolic stress caused by the mutation.10-12 
The increased import of lactate in IDH1 mut glioma cells re-
sults in a lower intracellular pH of tumor cells. Intracellular 
pH is tightly regulated in the cytoplasm within a narrow pH 
range (7.1-7.2) and is controlled by proton pumps and trans-
porters.15 Carbonate ions (HCO−
3
) and Na+ are the main ex-
tracellular ions that compensate for changes in pH.16 One of 
the most significant changed proteins in relation to the IDH1 
mut appeared to be SLC4A4. This protein is a transporter of 
Na+ and HCO−
3
 into the cell and regulates intracellular pH.17 
The increase of SLC4A4 in IDH1 mut cells is a mechanism 
to correct intracellular pH, in accordance with the increased 
import of lactate into IDH1 mut glioma cells.
Changes in glutaminolysis in relation to cancer are not 
unique to the IDH1 mut and have been reported in rela-
tion to various cancer types.18 A number of oncogenes and 
tumor suppressors like c-MYC, KRAS, and mTOR enhance 
or inhibit gene expression of enzymes involved in gluta-
minolysis.18,19 In most tumors the Warburg effect (aerobic 
glycolysis) causes an increased lactate production and an ex-
tracellular export of lactate. Our data and findings of Lenting 
and co-workers indicate that in IDH1 mut gliomas lactate is 
actively imported into the cell in contrast to the Warburg ef-
fect. This results in metabolic changes specific to IDH1 mut 
gliomas and tailored to the tumor microenvironment in which 
large amounts of both glutamate and lactate are present.20,21 
In both IDH1 mut glioma tissues and glioma cell culture 
models with the IDH1 mutation, a decrease in both glutamate 
and lactate levels is reported.22,23 These observations confirm 
our data and support an increased conversion of both lactate 
and glutamate into glioma cells with the IDH1 mut.
F I G U R E  2  Volcano plot from DDA analyses. On the x-axis the difference in the log2 intensity values between IDH1 mut and IDH1 wt is 
indicated. The y-axis represents the −log10 of the p-value from the t-test. The cut-off is based on an FDR of 0.05 based on 250 randomizations of 
the dataset. The proteins related to the glycolysis, pentose phosphate pathway, TCA cycle, glutaminolysis, fatty acid metabolism, GABA shunt, and 
amino acid catabolism are labeled and marked in red
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A lack of significant changes in abundance of glycolysis 
enzymes corroborates with our gene expression data and the 
findings of Lenting and co-workers.11 The glucose transporter 
(SLC2A3) and hexokinase 2 (HK2) were found downregulated 
in glioma samples with the IDH1 mut. We observed a decrease 
in protein level of the glucose transporter (SLC2A1), not the 
(SLC2A3) variant. A potential reason for discrepancies of our 
data from the transcriptomic data is the influence of non-tumor 
cells. The presence of erythrocytes or stromal cells in the gli-
oma tissue samples could potentially influence the measured 
values to some extent. The influence of non-tumor cells on 
SLC2A1 abundance could be significant as SLC2A1 is highly 
abundant in fully matured erythrocytes and brain endothelial 
cells. GBM samples are more vascularized than lower-grade 
tumors and could for this reason contain more erythrocytes and 
endothelial cells. The abundance of hexokinase variants, HK1 
and HK2, was increased in IDH1 mut glioma. Higher levels of 
HK1 abundance in low-grade gliomas is associated with nor-
mal oxidative respiration and this is indicative of a decrease in 
aerobic glycolysis.24 The data indicate that lactate is imported 
in IDH1 mut brain tumor cells. Lactate is used for the produc-
tion of pyruvate which is shuttled into the TCA cycle resulting 
in an increase in oxidative respiration. Oppermann et al have 
already shown that extracellular pyruvate can fuel the TCA 
cycle.25 In cell culture experiments of U87 (IDH1 wt) cells, 
it was observed that glucose can be replaced by pyruvate. In 
these cells, pyruvate is imported and the TCA-cycle interme-
diates citrate, α-ketoglutarate, and succinate are increased, in-
dicative of the utilization of extracellular pyruvate in the TCA 
cycle. In addition, in vivo experiments have shown that extra-
cellular lactate may be used as an energy source in the human 
brain.26 Expression levels of HK2 increase with glioma grade 
and the highest RNA expression and protein levels are found in 
GBM.24,27,28 However, we were unable to confirm this by pro-
teomics. In GBM cell lines it was shown that knocking down 
HK2 results in inhibition of the aerobic glycolysis leading to 
an increase in normal oxidative respiration and a decrease in 
lactate production. HK2 is crucial for the Warburg effect, in-
creasing aerobic glycolysis. Our findings corroborate this ob-
servation and indicate that aerobic glycolysis is increased in 
the IDH1 wt glioma, in contrast to IDH mut glioma.
Lenting and co-workers showed that the GABA shunt 
is upregulated in IDH1 mut glioma.11 ALDH5A1 is one of 
the proteins with the largest difference in abundance be-
tween IDH1 wt and IDH mut gliomas in the DDA analyses. 
ALDH5A1 converts succinic semi-aldehyde into succinate 
and is as such part of the GABA shunt. In addition, two 
other enzymes of the GABA shunt, DCE1 and ABAT, were 
investigated. For DCE1 we were not able to obtain quanti-
tative data, while for ABAT we observed a significant in-
crease in IDH1 mut gliomas indicating that the GABA shunt 
is upregulated. The increase in the GABA-shunt protein 
F I G U R E  3  Volcano plot from PRM analyses. On the x-axis the difference between the two groups is indicated in a log2 value. The y-axis 
represents the −log10 of the p-value from the t-test. The significance cut-off is based on an FDR of 0.05 based on 250 randomizations of the 
dataset. The significant proteins are labeled and marked in red
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ABAT, which introduces additional succinate to the TCA 
cycle, explains the increased levels of the TCA-cycle en-
zymes that further process succinate. Aldehyde dehydroge-
nase 6 (ALDH6A1) is involved in the valine and thymine 
catabolism and we found a significant change in abundance 
in relation to the IDH1 mutation in the DDA analysis.29 For 
this reason, amino acid catabolism was investigated in our 
targeted analyses. The enzymes involved in valine, leucine, 
and isoleucine catabolism (ECHS1, BCKHA, BCKHB, and 
HIBCH) were all significantly higher in abundance in IDH1 
mut glioma samples, confirming the increase in amino acid 
catabolism. Glutamate and α-ketoglutarate play central roles 
in the catabolism of these amino acids. Proline catabolism is 
affected and both OAT and ALDH4A1 levels are increased, 
indicating that proline is converted into glutamate. In addi-
tion, the transporters of glutamate, alanine, serine, cyste-
ine, and threonine (SLC1A2, SLC1A3, and SLC1A4) are 
increased. Taken together, this makes it likely that amino 
acid catabolism is increased for anaplerotic feeding of the 
TCA cycle. In addition, the presented data indicate that in 
IDH1 mut gliomas, compensation mechanisms are being 
activated to produce extra TCA-cycle metabolites to keep the 
TCA cycle active. It is, however, striking that the glycolysis 
route that fuels the TCA cycle is not increased (the glucose 
importer SLC2A3 RNA expression is even decreased11). 
The obstructed catabolism of glucose in IDH1 mut gliomas 
was reported before.11,22,30 By metabolic flux experiments 
T A B L E  2  Results of volcano plot analyses comparing IDH1 wt 
(GBM) with IDH1 mut (astrocytoma and oligodendroglioma)
Gene name
Significant 
FDR < 0.05 p-value
Ratio IDH1 
mut/IDH1 wt
GLUD1 + 2.06E-11 5.92
SLC16A3 + 5.88E-11 0.06
SLC1A2 + 2.37E-10 8.99
SLC4A4 + 2.74E-10 5.05
ACO2 + 2.89E-10 2.78
PC + 3.25E-10 3.11
GLUD2 + 4.44E-10 8.11
ABAT + 1.10E-09 3.67
PDHA1 + 1.28E-09 2.51
ECHS1 + 1.59E-09 2.41
SLC1A3 + 1.89E-09 3.07
SUCLA2 + 2.83E-09 2.40
SUCLG1 + 3.58E-09 2.66
SLC1A5 + 4.51E-09 0.17
LDHB + 5.96E-09 2.19
ALDOC + 1.15E-08 2.80
IDH2 + 1.39E-08 2.11
L2HGDH + 1.84E-08 3.08
GOT2 + 1.98E-08 2.62
G6PD + 2.14E-08 0.47
HIBCH + 2.88E-08 5.12
BCKDHB + 6.17E-08 1.96
GLS2 + 6.86E-08 5.31
PFKP + 7.24E-08 2.33
BCKDHA + 1.09E-07 2.04
GOT1 + 1.36E-07 4.16
ALDH4A1 + 2.50E-07 2.19
LDHA + 5.22E-07 0.53
TUBB + 9.09E-07 1.74
PGAM1 + 9.91E-07 1.79
MDH2 + 1.25E-06 1.78
GLUL + 1.37E-06 2.14
PFKL + 1.96E-06 1.46
HK1 + 3.02E-06 2.10
BCAT + 3.23E-06 0.47
TKT + 3.77E-06 1.64
PFKM + 3.83E-06 1.46
CS + 5.09E-06 1.61
SLC16A7 + 7.65E-06 3.08
OGDH + 9.25E-06 1.70
ALDH18A1 + 2.69E-05 0.48
SLC2A1 + 3.34E-05 0.54
HK2 + 4.78E-05 3.57
PGD + 3.62E-04 0.74
Gene name
Significant 
FDR < 0.05 p-value
Ratio IDH1 
mut/IDH1 wt
MLYCD + 4.06E-04 1.66
SDHA + 7.13E-04 1.37
ENO1   1.95E-03 1.30
ACACA + 3.17E-03 1.41
FH + 3.61E-03 1.58
OAT + 6.13E-03 1.44
D2HGDH + 1.04E-02 1.56
GLS + 2.12E-02 2.32
TPI1 − 2.57E-02 1.26
SDHB − 3.05E-02 1.36
SUCLG2 − 5.12E-02 1.33
IDH1 − 2.29E-01 0.78
PGK1 − 2.63E-01 1.23
SLC2A3 − 3.38E + 01 1.44
ACTC1 − 3.52E + 01 0.88
GPI − 7.15E + 01 1.17
PGLS − 7.01E + 02 0.89
PKM − 1.14E + 03 1.11
FASN − 9.08E + 05 1.17
GAPDH − 2.46E + 07 0.95
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in an IDH1 R132H patient-derived xenograft (PDX) it was 
shown that glucose is scarcely used as the carbon source 
for either α-ketoglutarate or 2-hydroxy-glutarate, indicative 
of the use of alternative carbon sources for the production 
of these metabolites to fuel the TCA-cycle.30 Recently by 
pH and oxygen-sensitive MRI imaging of glioma patients, 
large differences in the tumor microenvironment of IDH1 
wt and mut gliomas are observed. The authors suggest that 
these changes indicate that in IDH1 mut tumors the aerobic 
glycolysis is less active and the TCA cycle is more active 
which is in agreement with our findings.31
Our data and previously acquired RNA expression data 
are all an indirect read-out of the metabolome. A direct 
measurement of the metabolome itself could potentially be 
more accurate. The disadvantages of a metabolomics study 
are that fresh-frozen tissues are required. In addition, me-
tabolites are often involved in different chemical reactions 
which make it difficult to identify the exact reaction in which 
F I G U R E  4  Overlay of protein abundance data with metabolic pathways of the glycolysis, pentose phosphate pathway, TCA cycle, and 
glutaminolysis. The red arrows indicate an enzymatic reaction and the purple arrows represent transport of a metabolite over the cell membrane. 
The number next to each protein in the metabolic map represents the ratio between the IDH1 wt group and IDH1 mut group. A red asterisk 
indicates that the difference between the two groups is significant based on the volcano plot analyses with an FDR correction of 0.05 based on 
250 randomizations of the data. The glutaminolysis and the aerobic glycolysis appear to be affected mostly by the IDH1 mut
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F I G U R E  5  Abundance plots of the aerobic glycolysis and glutaminolyses based on PRM analyses. Abundance plots for panel (A) aerobic 
glycolysis and panel (B) glutaminolyses. In addition to the abundance plots of LDHA, LDHB, SLC16A3, and SLC16A7, the ratio between LDHA 
and LDHB and between SLC16A3 and SLC16A7 are displayed (panel A). The ratios indicate that predominantly in the IDH1 mut group lactate 
is transported into the cell and converted into pyruvate. The importer of glutamate (SLC1A2) and GLUD1 and GLUD2 (enzymes that convert 
glutamate into α-ketoglutarate) is increased in the IDH1 mut group (panel B). In all plots, the mean and SEM (standard error of the mean) are 
indicated for both groups, statistical differences (t-test) are indicated by asterisk's (**P-value < .001, ***P-value < .0001)
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changes occur. The protein content of a sample is usually 
less effected by sample collection procedures and can be 
extracted from FFPE material of which large collections are 
mostly available. Furthermore, enzymes catalyze very spe-
cific reactions; often (iso-)forms exist which are specific for 
a cellular compartment (mitochondrial, cytosolic) or tissue 
type. This information cannot be extracted from a metabo-
lomics study and intra- and extracellular concentrations of 
metabolites cannot be distinguished. For these reasons we 
have chosen a proteomics approach, although this represents 
an indirect way to measure enzymatic activity. In this re-
spect, we note that in an earlier study it was shown that RNA 
expression could be used as a surrogate to observe differ-
ences in the metabolism.32 As enzymes themselves are one 
step closer to the metabolome, their abundances should bet-
ter represent the activity of metabolic processes. Our find-
ings, however, need to be confirmed on the metabolic level, 
the lack of IDH1 mutant cellular and preclinical models and 
the appropriate biological context of the existing models 
makes it difficult to translate such findings to the patient sit-
uation.33 The altered metabolic processes probably largely 
depend on the microenvironment of the tumor cells result-
ing in rather large assumptions to translate findings from 
cell culture models to the in vivo situation. For this reason 
models that are closer to the in vivo situation, for instance, 
glioma PDX models have an advantage.34 A relative large 
panel of inhibitors that target enzymes or transporters of the 
glutamate metabolism exist.19 The inhibitors open possibil-
ities to target these enzymes in metabolic flux experiments 
in IDH1-mutated glioma PDX models to validate the find-
ings in this study. In addition are improvements made in 
MRI imaging which allow in vivo metabolic profiling of 
tumors.31,35
In conclusion, in IDH1 mut glioma significant differ-
ences in specific enzymes of the glutaminolysis and aerobic 
glycolysis are found. This proteomics study confirms and 
extends on earlier findings at the RNA expression level. 
The observations in IDH mut glioma are independent of 
tumor grade or molecular subtype of the tumor and affect 
predominantly the abundance of enzymes related to gluta-
minolysis. Based on these results we propose that the import 
of glutamate into IDH1 mut cells is increased as well as 
F I G U R E  6  Abundance plots based on PRM analyses. Abundance plots based on PRM analyses for ECHS1 and MLYCD (fatty acid 
metabolism) panel (A) for BCKHA, BCKHB, and HIBCH (valine, leucine, and isoleucine degradation) panel (B), and for ABAT (GABA shunt) 
panel (C). For all plots in the three panels the IDH1 mut group is compared with the IDH1 wt group. Statistical differences (t-test) are indicated 
by asterisks (***P-value < .001). All proteins were found to be statistically different except for MLYCD. For all analysis the mean value with the 
SEM is indicated
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the conversion of glutamate into α-ketoglutarate. Enzymes 
that convert proline, valine, leucine, and isoleucine into 
glutamate are also increased. Furthermore, the transport 
of lactate and the enzymes involved in the subsequent con-
version into α-ketoglutarate are increased. The increased 
intake of lactate results in intracellular acidification which 
is most likely compensated by an increase in the bicarbon-
ate transporter (SLC4A4). The metabolism seems to be re-
wired to produce additional α-ketoglutarate to preserve the 
TCA cycle as a survival mechanism for IDH1 mut gliomas. 
Further validation including metabolic flux experiment is 
required. The presented data aids in a better understanding 
of the role of the IDH1 mutation in glioma metabolism and 
can generate ideas how drugs can be designed to interfere 
with the specific energy requirements in IDH1 mut and 
IDH1 wt glioma.
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